News, Publications & Presentations Press Releases Featured • Mar 28, 2023 March 28, 2023: Partnership Announced with Boehringer Ingelheim Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients Covant Therapeutics News • Mar 7, 2023 Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement “This is a very exciting time for Covant as we continue to build our compelling pipeline of therapeutic programs” Iván Cornella, PhD In The News Featured • Mar 29, 2023 Forbes: Deals of the Week 2023 Covant Therapeutics announced an exclusive collaboration with Boehringer Ingelheim. Forbes News • Mar 29, 2023 Covant bonds with Boehringer in $481M covalency-driven oncology deal Boehringer Ingelheim GmbH has agreed to pay Covant Therapeutics Inc. $10 million for exclusive rights to the latter’s ADAR1-targeting immuno-oncology program. BioWorld News • Mar 29, 2023 Covant Therapeutics Debuts with Boehringer Partnership Targeting ADAR1 Boston-based Covant Therapeutics gained $10 million upfront in a deal with Boehringer Ingelheim to chase after a cancer immunotherapy target, ADAR1 (adenosine deaminase acting on RNA). Biospace News • Mar 29, 2023 Covant and Boehringer link up to create ADAR1 inhibitor for cancer patients The companies jointly aim to develop a novel small molecule immunotherapy targeting ADAR1 to transform the lives of cancer patients. The Pharma Letter News • Mar 29, 2023 Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies The deal to develop a small-molecule inhibitor could be worth over $480m PM Live News • Mar 28, 2023 With Boehringer Ingelheim’s help, Roivant churns out another Vant to go up against Endeavor, Impact founders Roivant Sciences has added another branch to its family tree, unveiling Covant Therapeutics with a $10 million upfront commitment from Boehringer Ingelheim to turn up the heat in cancer. Endpoints News
